That’s it for 2025’s Q1 clinical trials round-up. If you have a study that could fit the bill for our next column, please ...

The progress made in liver disease research to date presents an opportunity for further advancements in the near future.

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...

Bayer chief executive Bill Anderson has said that newer product launches have offset the decline in sales of anticoagulant ...

Improving Global Access to Life-Changing Therapeutics... Following the successful Boston and London meetings, the ...

Just a few months after announcing a plan to separate its drug and cell therapy businesses into two separate companies, ...

Netherlands biotech Azafaros is poised to start phase 3 trials of its lead drug for a trio of rare lysosomal storage ...

In the REAL8 basket trial, Sogroya (somapacitan), administered as a once-weekly subcutaneous injection, was at least as ...

The pharmaceutical industry is quickly evolving; to stay relevant and competitive, companies need to stay on top of the most recent trends and technologies. One important piece of the puzzle that ...

The pharma industry's challenge to Medicare drug price negotiation powers continues to rumble on, with three drugmakers asking a US appeals court to revive their lawsuits. Lawyers for AstraZeneca ...

As the demands of modern healthcare grow, new therapies are introduced at record speeds, and guidelines are quickly updated, it is key that medical education evolves to keep up. Traditional ...

The FDA has declined to approve two more cancer therapies developed by drugmakers based in China, in what may be further evidence of a tough line taken by the regulator for drugs tested outside ...